Neucruit: Creating a platform to optimise participant recruitment for active COVID-19 vaccine trials, and future clinical and research trials.

点击翻译按钮获取中文摘要

Clinical research trials protect patients from experimental medical research and ensure that new vaccinations are safe and effective before they're scaled. On average, researchers spend 30% of R&D securing participant recruitment. When the criteria for participation is complex, it can take up to 7 months to find participants (CRM International-2011). Over 86% of clinical research is delayed by up to 6-months due to delays in participant recruitment, translating into even longer delays for patients who need life-saving treatments (Applied Clinical Trials-2004).To understand the nature, effects and suppression of COVID-19, extensive trials are needed. Trials are likely to include vaccinations and asymptomatic patient testing to understand how the disease is spread. There are approximately 150 COVID-19 vaccination trials awaiting testing, requiring on average 650 participants per trial (Harden-2018). Research facilities around the world are attempting to urgently fast-track a vaccine. Access to a network of pre-screened participants will make vaccinations a reality, quickly.Neucruit's innovation combines an optimised platform for managing recruitment of clinical trials, with intelligent algorithms for pre-selection and matching using AI.Neucruit will optimise participant recruitment via a web-based platform, which matchmakes clinical researchers with a large population of patients, and digitalises contact time for risk reduction.In this project we will develop the Neucruit platform to MVP, onboard a minimum 9,000 participants and test our software in three live Phase III COVID-19 vaccination trials.